The genes affected by semaglutide included markers of inflammation and plaque stability that are associated with leukocyte recruitment [e.g., interleukin-1 (IL-1) receptor antagonist, IL-6, monocyte chemoattractant protein (CCL2), OPN], leukocyte adhesion [selectin E, vascular cell adhesion molecule-1 (VCAM1)], leukocyte extravasation and plaque stability (e.g., MMP3, MMP13, CCL2), and plaque rupture and hemorrhage (CD163)
The once-weekly patch uses dissolving microneedles to deposit drug into the dermis and is built on Daewoong Therapeutics CLOPAM platform, which employs pressurized drying and sealed packaging to stabilize dosing
What FDA's Latest Actions Mean for Peptide Compounding (Federal Register Docket FDA-2025-N-6895
January 13th, 2026: Court Holds First Status Conference in Ozempic Vision Loss MDL U.S
Role of microglia in autism: recent advances